Eurosurv. Supplementing SARS-CoV-2 genomic surveillance with PCR-based variant detection for real-time actionable information, the Netherlands, June t

[tetano]

• Richard Molenkamp[SUP]1[/SUP] , Ewout Fanoy[SUP]2[/SUP] , Leonie Derickx[SUP]3[/SUP] , Theun de Groot[SUP]4[/SUP] , Marcel Jonges[SUP]5[/SUP] , Tjalling Leenstra[SUP]6[/SUP] , Roel Nijhuis[SUP]7[/SUP] , Suzan Pas[SUP]8[/SUP] , Ali Vahidnia[SUP]9[/SUP] , Christian von Wintersdorff[SUP]10[/SUP] , Bert Mulder[SUP]4[/SUP] , Marion Koopmans[SUP]1[/SUP]

We evaluated routine testing with SARS-CoV-2 Delta variant-specific RT-PCR in regional hospital laboratories in addition to centralised national genomic surveillance in the Netherlands during June and July 2021. The increase of the Delta variant detected by RT-PCR correlated well with data from genomic surveillance and was available ca 2 weeks earlier. This rapid identification of the relative abundance and increase of SARS-CoV-2 variants of concern may have important benefits for implementation of local public health measures.

full article

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.40.2100921